IFN-β has been proven effective for the treatment of relapsing remitting MS[7]: IFN-β decreases the relapse rate, ameliorates disease activity and reduces the number of inflammatory CNS lesions[9]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.